Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/02/26	29.02 $	+8.61%	192,991
11/02/26	26.72 $	+0.15%	56,442
10/02/26	26.68 $	-3.73%	77,598
09/02/26	27.72 $	+1.78%	113,426
06/02/26	27.23 $	+8.62%	118,788

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 21:00:00 12/02/2026 GMT			5-day change	1st Jan Change
29.02 ^USD	+8.61%		+15.76%	+38.19%

31/10/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
30/10/25	Regencell Bioscience Holdings Limited Auditor Raises 'Going Concern' Doubt	CI

Capitalization	14.35B 12.09B 11.04B 10.53B 19.56B 1,300B 20.23B 128B 50.98B 626B 53.82B 52.71B 2,187B	P/E ratio 2024	-10.2x	P/E ratio 2025	-2,351x
Enterprise value	14.35B 12.09B 11.03B 10.53B 19.56B 1,300B 20.22B 128B 50.96B 626B 53.8B 52.7B 2,187B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	11.18%	Yield 2024 *	-	Yield 2025	-

31/10/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
30/10/25	Regencell Bioscience Holdings Limited Auditor Raises 'Going Concern' Doubt	CI
22/09/25	Regencell Bioscience Holdings Limited(NasdaqCM:RGC) added to S&P Global BMI Index	CI
30/06/25	Regencell Bioscience Holdings Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
30/06/25	Regencell Bioscience Holdings Limited Announces Board Changes, Effective June 30, 2025	CI
25/06/25	Top Premarket Gainers	MT
23/06/25	Top Premarket Decliners	MT
20/06/25	Top Premarket Decliners	MT
18/06/25	Top Premarket Decliners	MT
17/06/25	Top Premarket Gainers	MT
17/06/25	Regencell Bioscience Extends Gains Pre-Bell Tuesday Following 276% Surge Monday	MT
16/06/25	Top Premarket Gainers	MT
02/06/25	Regencell Bioscience Approves 38-For-One Forward Stock Split	RE

11-20	Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regencell Bioscience Holdings Limited - RGC	PR
20/06/24	Regencell Bioscience : Announces First Half 2024 Financial Results Form 6 K	PU
02/01/24	Regencell Bioscience : Resignation of Yi-Chung Chao as Director - Form 6-K	PU
15/12/23	Regencell Bioscience : Form of Letter of Lock-up Undertaking - Form 6-K	PU
15/06/23	Regencell Bioscience : Announces First Half 2023 Management Financial Results - Form 6-K	PU

Regencell Bioscience Holdings Limited Share Price

Equities

RGC

KYG7487R1002

Biotechnology & Medical Research

Valuation: Regencell Bioscience Holdings Limited

Chart: Regencell Bioscience Holdings Limited

Latest news: Regencell Bioscience Holdings Limited

Analysts' recommendations: Regencell Bioscience Holdings Limited

Press Releases: Regencell Bioscience Holdings Limited

News in other languages: Regencell Bioscience Holdings Limited

Quotes and Performance

Course Extremes

Managers and Directors: Regencell Bioscience Holdings Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

27/06/25	El milagro de las hierbas : esta acción sube un 20.000% en un año sin vender nada
18/02/22	La formule liquide expérimentale RGC-COV19TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de...
17/02/22	La formulazione liquida sperimentale RGC-COV19TM di Regencell Bioscience si dimostra efficace nell'eliminazione dei sintomi di COVID-19 da lievi a moderati nei pazienti arruolati nello studio di efficacia EARTH, in un periodo di trattamento di 6...
17/02/22	Flüssigprüfformel RGC-COV19TM von Regencell Bioscience zeigt Wirksamkeit bei den rekrutierten Patienten in der Wirksamkeitsstudie EARTH und behebt leichte bis mäßige COVID-19-Symptome innerhalb von 6 Tagen
17/02/22	Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días

1 day	+8.61%
1 week	+15.76%
Current month	+16.13%
1 month	-34.21%
3 months	+112.13%
6 months	+115.92%
Current year	+38.19%

1 week	25.8	30.39
1 month	20.81	37.99
Current year	20.5	69
1 year	0.09	83.6
3 years	0.08	83.6
5 years	0.08	83.6
10 years	0.08	83.6

Manager	Title	Age	Since
Yat-Gai Au CEO	Chief Executive Officer	54	31/12/2013
Wai Hong Chung COO	Chief Operating Officer	49	31/07/2021

Director	Title	Age	Since
Wai Hong Chung BRD	Director/Board Member	49	27/12/2023
Yee Wah Hui BRD	Director/Board Member	54	30/06/2021
Wing Yan Lo BRD	Director/Board Member	65	12/12/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
REGENCELL BIOSCIENCE HOLDINGS LIMITED	+8.61%	+15.76%	+29,391.87%	+3,835.45%	13.21B
LONZA GROUP AG	-1.74%	-3.90%	-16.81%	-8.35%	46.14B
BEONE MEDICINES AG	-1.38%	-0.17%	+55.13%	+41.70%	38.87B
CELLTRION, INC.	-0.42%	+9.66%	+38.80%	+60.37%	36.18B
IQVIA HOLDINGS INC.	-4.70%	-6.69%	-14.64%	-24.23%	30.05B
REVOLUTION MEDICINES, INC.	-0.67%	+1.23%	+131.74%	+295.97%	18.94B
IONIS PHARMACEUTICALS, INC.	-3.05%	-2.04%	+165.18%	+109.69%	13.66B
ASCENDIS PHARMA A/S	-1.53%	+0.33%	+72.90%	+91.40%	13.6B
EUROFINS SCIENTIFIC SE	-1.05%	-6.49%	+26.82%	-5.13%	13.55B
MEDPACE HOLDINGS, INC.	-1.86%	-23.14%	+23.65%	+86.12%	12.03B
Average	-0.78%	-1.64%	+2,987.46%	+448.30%	23.62B
Weighted average by Cap.	-1.22%	-0.97%	+1,680.81%	+265.34%

	2024	2025
Net sales	-	-
Net income	-4.3M -3.63M -3.31M -3.16M -5.86M -390M -6.06M -38.43M -15.28M -188M -16.13M -15.8M -656M	-3.58M -3.02M -2.76M -2.63M -4.89M -325M -5.05M -32.02M -12.73M -156M -13.44M -13.17M -546M
Net Debt	-7.88M -6.64M -6.06M -5.78M -10.74M -714M -11.1M -70.36M -27.98M -344M -29.54M -28.93M -1.2B	-4.35M -3.67M -3.35M -3.2M -5.93M -394M -6.14M -38.88M -15.46M -190M -16.32M -15.99M -663M